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ABSTRACT 
AIM: To evaluate incidence of sensorineural hearing loss & retinopathy in 
patients with diabetes mellitus. To correlate association of sensorineural 
hearing loss with retinopathy in patients with diabetes mellitus. 
METHOD AND MATERIAL: A sample of 92 subjects are selected by 
blind randomization & divided into cases & controls of 46 individuals in 
each. Detailed clinical examination of ear & eye is performed, including 
tunning fork tests fundoscopy & subjected to investigations. The data 
collected from these tests & investigations are subjected to appropriate 
statistical tests to arrive suitable conclusions. 
RESULT: In our study 73.9% of cases had diabetic retinopathy and 89% of 
cases had sensory neural hearing loss with significant P value. 
60.8% cases with >2years of DM had retinopathy. About 39.1% cases of 
retinopathy had DM for >4 years. 4 out of 5 cases of PDR had DM > 6 years. 
65.2% of cases with SNHL had DM > 2years of which 41.3% cases with 
SNHL had DM >4 years. 
 Cases with HbA1C >7, 71.7% of them had retinopathy of which 
43.47% of them had HbA1C >8. Similarly 84.7% of cases having SNHL had 
HbA1C >7 of which 41.35% had HbA1C >8. 
47.8% of cases having SNHL >41dB (>/=moderate SNHL) had retinopathy of 
grade 2 NPDR or higher severity of retinopathy. It is highly significant that 
diabetics with greater SNHL have more severe retinopathy with P value: - 
<0.01. 
 
  
 
CONCLUSION: A statistically significant correlation was found between 
SNHL and the severity of diabetic retinopathy. More severe grades of SNHL 
and retinopathy manifesting in patients with higher levels of HbA1C and 
prolonged duration of DM. 
KEY WORDS: relationship between SNHL and diabetic retinopathy, SNHL 
among diabetics with retinopathy, PTA and fundoscopy in diabetics. 
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INTRODUCTION 
Auditory & visual senses being the most important sense organs among 
the five, are needed almost for every day to day activities in our life. Any 
condition or disease causing impairment in hearing & vision can disturb the 
normal well being of an individual. One of such disease is Diabetes mellitus. 
India has 2nd largest diabetics in the world according to WHO (61.3 million, or 
8% of the population).6. And the number is expected to increase to a staggering 
79.4 million by 2030. 
Diabetes mellitus is a metabolic disorder, due to relative or absolute 
lack of insulin resulting in elevated blood glucose levels associated with long 
term vascular and neurological complications.5.   It affects almost all the 
systems in the body to its severity if left uncontrolled. Likewise, diabetic 
hearing loss results from microangiopathic involvement of endolymphatic sac 
and/or basilar membrane vessels.4. The typical hearing loss in diabetes is 
described as a progressive, bilateral, sensorineural type deafness of gradual 
onset which affects predominantly higher frequencies and elderly patients. 
There is a decrease in auditory acuity which is similar to that due to 
presbyacusis, but those affected show a hearing loss greater than that could be 
expected at that age.2,3. Exceptions to this pattern have been reported including 
acute onset of hearing loss or associated with Meniere like attacks, unilateral 
deafness with or without vestibular symptoms and low frequency involvement.  
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The effect of diabetes mellitus on hearing is known since 1857, when Jordao 
first showed hearing loss in a patient with incipient diabetic coma. 1. 
The retina is affected by many systemic disorders, one of which is 
diabetes mellitus (DM). An exponential increase in the global number of 
diabetic patients couples with a rise in life expectancy due to better medical 
care, has resulted in a proportionate rise in long term vascular complications 
such as diabetic retinopathy (DR). 
Diabetes mellitus is a major cause of avoidable blindness in both the 
developing and the developed countries. Patients with diabetic retinopathy 
(DR) are 25 times more likely to become blind than non-diabetics 
Diabetic retinopathy is a highly specific microvascular complication of 
diabetes and is characterized by abnormal retinal vascular permeability, 
microaneurysm formation, capillary and arteriolar closure, neovascularization 
and associated haemorrhage, scarring, and tractional retinal distortion and 
detachment. 
Diabetic retinopathy is the commonest cause of blindness in the working 
population, causing an estimated 50-65 new cases of blindness per 1,00,000 
people every year.7, 8. 
This case control study is done to compare auditory acuity & 
retinopathy in non-diabetic & diabetic patients to find out the affect of diabetes 
on auditory acuity. 
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AIM OF THE STUDY 
1. To evaluate incidence of sensorineural hearing loss & 
retinopathy in patients with diabetes mellitus. 
2. To correlate association of sensorineural hearing loss with 
retinopathy in patients with diabetes mellitus. 
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OBJECTIVE OF THE STUDY 
1.  To correlate sensorineural hearing loss & retinopathy with duration of 
disease.  
2.  To correlate incidence of sensorineural hearing loss & retinopathy 
according to age & sexual predominance in diabetes mellitus. 
3.  To correlate severity SNHL & retinopathy according to glycemic 
control (HbA1c). 
4.  To asses association between retinopathy with sensory neural hearing 
loss among diabetics. 
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REVIEW OF LITERATURE 
Historical review: 
A. DIABETES MELLITUS 
 YEAR  
 
EVENT 
Over 3500 years - Polyuric states similar to diabetes 
mellitus were described.  
The name Diabetes came from the 
Greek word for a ‘syphon’  
First millennium - The sweet taste of urine was 
recognized  
1776 - Mathew Dobson stated that diabetes 
was a systemic condition and not a 
disease of the kidney and that diabetic  
urine and serum tasted sweet  
Eighteenth century - John Rollo added ‘mellitus’ meaning 
‘honeyed’  
1815 - Chevreul identified excess sugar in 
diabetes as glucose.  
1840 - Claude Bernard showed that glucose 
was normally present in the body and 
is stored in the liver as glycogen and is 
secreted into the blood stream during 
fasting.  
1864 - Marchal de calvi identified the 
association of neuropathy with 
diabetes mellitus.  
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1869 - Paul Langerhans showed the 
production of an internal secretion in 
the pancreas which could regulate 
glucose metabolism.  
1880 - Etienne Lancereaux divided diabetes 
into diabetes maiqre (lean subject) and 
diabetes obese gras (obese)  
1880 - Stephan Mackenzie and Edward 
Nettleship identified specific lesions 
microaneurysm in blood vessels.  
1889 - Oscar Minkowski and Josef von 
Mering demonstrated the role of 
pancreas in diabetes by producing 
diabetes in a dog by pancreatectomy.  
1893 - Gustave Laguesse showed that 
pancreatic islets produced  
internal secretions that regulated 
glucose metabolism  
1900-1920  Georg Zuelzer and Nicholas Pauluco 
attempted to isolate  Insulin  
1909 - Jean de Meyer gave the name 
‘insulinine’ to the then  
hypothetical products of the islets.  
1921 - Fredrick Banting, Charles Best and 
James Collip discovered insulin at the 
university of Toronto in acid-  
ethanol extracts of pancreas and won 
the Nobel prize in 1995  
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1930 - Wilhelm Falter and Harold Hims 
classified diabetes into ‘insulin 
sensitive’ and ‘insulin nonsensitive’ 
types.  
1940 - Production of synthetic human 
sequence insulin.  
1950 - Kund Lundbaek described a particular 
type of angiopathy that was specific to 
diabetes.  
1955 - Frederick Sanger and Dorothy 
Hodgkin described the primary 
sequence of insulin  
1956 - Rosalyn Yalow and Solomon Berson 
invented the radioimmunoassay for 
insulin.  
1965 - Willy Gepts highlighted the 
significance of chronic lymphocytic 
infiltrations in the islets of 
Langerhans.  
1969 - Fredrick Sanger and Dorothy Hodgkin 
described the molecular three 
dimensional structure of insulin.  
1971 - Pierre Freyet discovered the presence 
of insulin receptors.  
1974 - Robert Tattersall described MODY as 
a distinct variant of diabetes mellitus.  
1980 – 
 
Graham Bell described the sequence 
of human insulin gene. 
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B. OTOLOGICAL ASPECT: 
6th century BC - 
 
Pythagoras, a philosopher and a 
mathematician, reasoned that sound 
was a vibration in the air. 
175 AD - Galen, a Greek physician recognized 
that nerves transmitted the sensation 
of sound to the brain.  
1200 AD -  Recognition of the fact that sounds 
entered the interior of the ear via the 
eardrum and exited on its journey to 
the brain via the auditory nerve.  
1543 AD - Vesalius described the ossicles and 
applied the name ‘labyrinth’ to the 
ear.  
1550 AD - Eustacius described the pharyngo 
tympanic tube.  
1561 AD - Gabriello Fallopio, an Italian 
professor discovered the ‘cochlea’.  
1600 AD - Felix Platter, a physician from 
Switzerland studied of the bones of 
the ear and commented on the 
phenomena of conduction of sound 
through the bones of the head. He said 
that the cause of deafness was 
sometimes in the brain (sensorineural 
or central deafness) and sometimes in 
the cavity of the ear (conductive).  
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1640 AD - Willis of England described the 
cranial nerves and said that the 
tympanic membrane was set into 
motion by sounds and the vibrations 
thus set up were transferred to the 
inner ear and to the auditory nerves.  
1704 AD - Valsalva divided the ear into three 
anatomical parts and developed the 
Valsalva’s maneuver. 
1800 AD  Cotugno discovered the fluids of the 
inner ear and described the fibers of 
the basilar membrane.  
1801 AD  Flourens of Paris, discovered the 
action of semicircular canals and 
suggested that the ‘nerve for hearing’ 
had two branches, one for hearing and 
one for balance.  
1825 AD  Weber worked with tuning forks for 
testing hearing and the test was later 
called ‘Weber’s test’.  
1851AD  Alfonso Corti, an Italian anatomist 
discovered that the organ within the 
cochlea is the true centre for hearing 
which is now named as ‘organ of 
Corti’. He also caught a glimpse of the 
thousands of hair cells that are now 
known to be the central elements in 
the hearing apparatus.  
1855 AD  Rinne tests hearing using tuning forks 
and calls it ‘Rinne’s test’  
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1857 AD  Hermann von Helmholtz reasons that 
the sound of different frequencies are 
detected at different sections of the 
organ of corti and publishes his ‘tonal 
theory of hearing’ which states that 
the parts nearest to the ossicles are 
sensitive to high tones and parts 
further from the ossicles to low tones.  
1941 AD  Barany in Vienna, wins the NOBEL 
PRIZE for developing methods of 
testing the organ of balance that would 
enable the clinician to differentiate 
between tumors of the 
vestibulocochlear nerve and neuronitis 
of the vestibular end organ and 
physiological nystagmus.  
1928 AD  Georg von Bekesy, an engineer for the 
Hungarian telephone exchange 
system, begins to use large scale 
models of cochlea to determine 
precisly how sounds of different 
frequencies stimulate basilar 
membrane and won NOBEL PRIZE. 
C. AUDIOLOGICAL ASPECT 
 
1897 AD  
 
1st basic model for a pitch range 
audiometer was developed by 
Seashore in Iowa.  
1947 AD  Bekesy introduced a technique for 
semi automatic audiometry which 
found application in both standard 
threshold determination and site of 
lesion testing.  
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1957 AD  Cahart added the tone decay test to the 
site of lesion test battery.  
1960 AD  Ruben et al. recorded cochlear 
potentials and compound action 
potentials of vestibulo-cochlear nerve.  
1967 AD  Bocca and Calero reported the 
methods of clinical identification and 
evaluation of central auditory 
deafness.  
C. DIABETIC RETINOPATHY ASPECT: 
1846 French ophthalmologist and     
Professor of Hygiene in Paris, 
Appolinaire Bouchardat reported the 
development of visual loss in the 
absence of cataract in diabetics. 
1851 Herman Von Helmholtz              
introduced the first ophthalmoscope. 
Eduard 
Jäger who constructed an instrument 
which integrated in one apparatus the 
principles of 
Helmholtz’s, Ruete’s and other 
ophthalmoscopes. 
1855 Jäger was the first to observe diabetic 
macular changes. 
1869 Henry Noyes published an article in      
the USA supporting the link 
between diabetes mellitus and 
maculopathy. 
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1876 Edward Nettleship presented the first 
histopathological proof of a cystoids 
degeneration of the macula in diabetic 
patients 
1890 Julius Hirschberg in 1890, classified 
diabetic retinopathy into four types 
(retinitis centralis punctuate, 
haemorrhagic form, retinal infarction 
and haemorrhagic glaucoma), thus 
describing the full natural history of 
diabetic retinopathy. 
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REVIEW OF LITERATURE 
Around 278 million people in the world have moderate to profound 
hearing loss,11. and have proved that more than half of the cases can be 
prevented by early diagnosis and management. Hearing loss which has a 
marking impact on an individual, families, health system and a country can be 
managed by provision of hearing aids after a precise diagnosis. The pathetic 
situation is that one out of the forty deaf in a developing country, gets a 
hearing aid, of which India is one.11.India takes a big bite in the diabetic 
population of the world with 50 million people.12. The Indian population with 
an increased susceptibility to diabetes mellitus is expected to double by 
2030.11 
Occurrence of hearing loss in diabetes mellitus patients is known 
since1857, when Jordao reported hearing loss in a patient with incipient 
diabetic coma.1 The diabetic influence on sensory neural hearing loss has been 
studied by Jorgen (1961)52 with aid of temporal bone of diabetic patients and 
reported a condition unique to diabetes mellitus as accumulation of Periodic 
Acid Schiff (PAS) positive substance in the modiolus vessels and capillaries of 
stria vascularis in various degrees.10 The study was carried over by Costa 
(1961) in animal models. With no particular pathological localization there 
was increase in the thickness of the basement membrane of the capillaries in 
stria vascularis and the changes were not bilateral. No changes were found in 
the spiral ligament. The basal cell layer was found disorganized and 
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vacuolization of light cells were found. In some turns of cochlea there was 
certain degree of degeneration of the endothelial cells of vestibular margin. 
With advent of 8 months of diabetic duration, the external sulcus cells of basal 
turns showed degenerative changes. The organ of corti, ganglion cells or nerve 
fibres showed no structural changes. Temporal bone sections showed 
increased thickness in vessel walls of modiolus. The  endothelial cells were 
swollen and the basement membrane was much thicker when compared to 
normal control rats. The changes were not at all related to the duration of 
diabetes.14 Zelenka & Kzak denied the significance of hearing loss in diabetics 
with the duration of disease, age of the patient, blood sugar level, blood 
pressure, bleeding in labyrinthine vessels which was postulated at that 
period.15 The spiral ganglion was found atrophied in the middle turn of 
cochlea. Fibrous thickening and narrowing of the lamina were observed in 
small arteries of internal auditory canal and in the capillaries of stria 
vascularis. 
The detailed study about pathological changes of the inner ear and 
central auditory pathway in diabetics was studied by Makishima and Tanaka.16 
Rust restricted his study to type 2 diabetics and degree of inner ear damage. 
He suggested that outer hair cell loss was prominent and was related to 
hyperglycemia, especially in patients who had genetic predisposition to 
glucose intolerance. The diabetic neuropathy in the auditory system was 
attributed to microangiopathy13 by Proctor in 1977, based on the hypothesis 
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that peripheral and central neuropathies in diabetes mellitus may affect 
vestibular neurons. Later Friedman studied diabetic patients with no 
complaints of decreased hearing and found a 55% prevalence of sensorineural 
hearing loss involving at least one frequency.18 This study revealed that 
sensorineural hearing loss was untouched by the age of the patient and the 
hearing loss was similar at low and high frequencies adding to the 
contradictory views. Diabetic patients have poorer hearing thresholds than non 
diabetics.19 
Diabetic retinopathy, one of the early manifestations of the late 
complications of diabetes mellitus was studied in relation to hearing loss by 
Miller and postulated that there was no significant difference in the hearing 
threshold from those of the control12 
population, but poor speech perception in the diabetic group was 
observed.20 The subtle retrocochlear hearing loss was denied by brain stem 
evoked responses in diabetics and non diabetics. Diabetics with peripheral 
neuropathy in association to sensorineural hearing loss was carried out by 
Mehra and observed a prevalence of 25%.21 In the brainstem auditory evoked 
responses waves III , IV and V were delayed in diabetics in comparison to the 
control population. 
The clinical and histopathlogical correlation in hearing loss established 
diabetics was studied by Wackym and observed that diabetics had more 
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hearing loss than the control of same age group. The diabetic group with 
hearing loss had microangiopathy.4 In 1989 Kurien studied the variation in 
hearing threshold in diabetics and published his study result as poor control of 
blood sugar levels and complicated diabetic history had high frequency 
hearing loss in comparison with well controlled diabetic history. No 
correlation of hearing threshold and diabetic duration was found.22 
Various factors that are responsible for hearing loss in diabetics are 
duration of diabetes, age, sex, etc. Certain studies show positive correlation 
between duration of diabetes and hearing loss3, but some say it has no 
relation.2,22 The reason stated for having no relation is that microangiopathy, 
does not depend on duration, but on control of diabetes. If there is poor control 
of diabetes, then hearing threshold increases.2 
In 1993 Cullen and Cinnamon compared hearing loss in insulin 
dependent diabetics and controls of same age and sex. They reported that there 
was a increased male morbidity involving variable frequencies and duration of 
diabetes having no effect on the hearing threshold.2 The typical hearing loss in 
diabetes mellitus is slowly progressive, bilateral sensorineural hearing loss 
affecting higher frequencies.2,23 
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But, that of, sudden onset unilateral Sensorineural hearing loss affecting 
lower frequencies is also found in some cases of diabetes mellitus.2,23 
Certain studies state that increase in hearing threshold in diabetics is for 
low frequencies (500 Hz), but some authors say it is present only in high 
frequencies (6000Hz and 8000Hz).2 The study showing positive correlation in 
low frequencies was conducted in IDDM patients, it was drawn that insulin 
might limit the progression of hearing threshold in higher frequencies. This 
finding of sensorineural hearing loss in diabetics indicated a disturbance 
somewhere in the central auditory pathway or in the inner ear.3 
To show the direct evidence of poor metabolic control over 
sensorineural hearing loss, levels of fasting blood glucose and HbA1C were 
measured at the time of conducting audiometry. But their levels were not 
systematically associated with elevated threshold of 6000 and 8000Hz.3 But 
poor metabolic control have indirect effects like diabetic retinopathy and 
nephropathy which are clearly associated with sensorineural hearing loss. 
The three main theories of pathogenesis of hearing impairment in 
diabetics are angiopathy, neuropathy and alterations in the inner ear glucose 
levels.3,24 There is also a possibility of hair cell dysfunction in diabetics as 
suggested by vascular thickening around endolymphatic sac causing 
accumulation of toxic waste products in endolymph.2 
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P.C.Chamyal advocated 40% sensorineural hearing loss prevalence in 
diabetics, involving higher frequencies and duration of diabetes had no effect 
on the hearing threshold.25 In 1998 Aggarwal opined through his study that in 
diabetics with hearing loss there was 64% sensorineural and 21% conductive 
component.26 
Sensorineural hearing impairment results from disorders of the cochlea, 
eighth cranial nerve, or cochlear nuclei. Generally sensorineural hearing 
impairment is irreversible and usually cannot be alleviated surgically or by 
medical intervention.31 
Sensorineural hearing impairment is usually managed through aural 
rehabilitation or habilitation including amplification.31 The acquired causes of 
sensorineural hearing loss are:32 
Acquired causes of SNHL  
1. Idiopathic 
2. Trauma  
3. Drugs (aminoglycosides, furosemide, salicylates, cisplatinum, quinine, 
thalidomide)  
 
 
19 
 
4. Noise induced  
5. Aging  
6. Systemic disease (hypothyroidism, chronic renal failure, diabetes mellitus)  
7. Infection  
8. Acoustic schwannomas  
Out of this the present study aims at type 2 Diabetes Mellitus in the 
middle age group. 
 TYPE II DIABETES MELLITUS 27,34  
Type II DM, is the predominant form of diabetes world wide 
accounting for 90% of cases.35 It has reached an epidemic status in both 
developed and developing countries and has become one of the world’s most 
important public health problems.36  
Sex, age and ethnic background are important factors in determining 
the risk for the development of type II DM. It appears that this disorder is 
more common in females.  
The World Health Organization34 has laid down strict criteria for the diagnosis 
of DM which are: 
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1. Symptoms of diabetes mellitus (polyuria, polydypsia, and weight loss) plus 
a random blood sugar of greater than or equal to 200mg/dl (on at least two 
separate occasions) OR  
2. Fasting blood sugar greater than or equal to 126mg/dl on at least two 
separate occasions. OR  
3. Two hour plasma glucose greater than or equal to 200mg/dl during an oral 
glucose tolerance test.  
The pathogenesis of type II DM is complex and involves interaction of 
genetic and environmental factors. It essentially comprises of three cardinal 
abnormalities: 33  
· Peripheral insulin resistance, 
· Defective insulin secretion, 
· Increased glucose production.  
There is an emerging consensus that most of the common forms of type 
II DM are due to a combination of insulin secretion abnormality and insulin 
resistance. In other words, diabetes results in a genetically predisposed 
individual with pancreatic beta cells that is unable to adapt to the reductions in 
insulin sensitivity that occur over a lifetime of the individual and is related to 
puberty, pregnancy, sedentary life style and over eating leading to obesity. 
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Clinically, the sequence noted is initial normal plasma glucose levels despite 
demonstrable insulin resistance. This is followed by worsening resistance 
leading to post prandial hyperglycemia. Finally, a decreasing insulin secretion 
and an unchanged insulin resistance lead to fasting hyperglycemia and overt 
diabetes. It has been observed that most of the insulin resistance is of the post 
receptor type. Insulin resistance is a consistent finding and is present years 
before the onset of diabetes. It implies the presence of an impaired biological 
response to either exogenously administered or endogenously secreted insulin. 
 The disposal of glucose after a meal depends on the ability of insulin to 
increase peripheral glucose uptake and simultaneously decrease endogenous 
glucose production. It appears that in type II DM, there is a defect in the 
regulation of glucose production from the liver which utilizes glycogenolysis 
and gluconeogenesis to produce glucose.34 Under different conditions and at 
different times in the post prandial 
period, the contribution of each of these pathways to maintain glucose 
may vary. Chronic complications of diabetes mellitus may affect multiple 
organ systems and are responsible for majority of morbidity and mortality 
associated with disease.  
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They are divided into:  
1. MICROVASCULAR  
a. Neuropathy  
- Sensory and motor  
- autonomic  
b. Eye Disease  
- Retinopathy ( proliferative , non proliferative )  
- Macular edema  
c. Nephropathy  
2. MACROVASCULAR  
a. Coronary artery diseases  
b. Peripheral Vascular diseases  
c. Cerebro vascular diseases  
3. MISCELLANEOUS  
a. Gastro instestinal  
b. Genitourinary  
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c. Dermatologic manifestations  
d. Infectious diseases  
e. Cataract  
f. Glaucoma  
g. Hearing loss 
The risk of chronic complication increase as a function of duration of 
hyperglycemia which becomes apparent in the second decade of 
hyperglycemia. As type II diabetes mellitus has a long asymptomatic period 
these patients are diagnosed mostly based on the complications. Randomised 
clinical trials have demonstrated that a reduction chronic hyperglycemia 
prevents or delays neuropathy, retinopathy or nephropathy. Genetic 
susceptibility to develop the particular complications have also been 
implicated.  
The complication of DM, are underlined by three pathological 
mechanisms namely, microangiopathy, neuropathy, or a combination of 
both.28 The diabetic specific microangiopathy is seen in the retina and the 
renal glomerulus along with the peripheral vascular circulation. Its role in 
microcirculation of the inner ear is controversial. Diabetes is also associated 
with an accelerated atherosclerotic macrovascular disease which is more 
extensive and progressive. Several studies have demonstrated a strong 
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relationship between glycemia and diabetic microvascular complications. This 
is continuous though not linear in nature. 
  Chronic hyperglycemia is the central initiating factor for all types of 
diabetic microvascular disease.34 The duration, magnitude of hyperglycemia 
are both strongly correlated with the rate and extent of progression of 
microvascular disease. It appears that hyperglycemic damage is limited to 
those cell types that develop intra cellular hyperglycemia for example, 
endothelial cells. These cells cannot down regulate glucose transport when 
exposed to extracellular hyperglycemia. 
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Applied Anatomy of Inner Ear 35 
The inner ear or labyrinth is situated in the petrous part of temporal 
bone and is divided into bony and membranous parts. The bony labyrinth 
houses the sensory organs and soft tissue structures of the inner ear and 
consists of cochlea, three semicircular canals and vestibule. Its bone has three 
layers, inner endosteal, middle enchondral and outer periosteal layers. The 
membranous labyrinth contains the sensory epithelium of cochlea and 
vestibular structures and it lies within the cavities of bony labyrinth. 
 
Figure-1:structure of ear. 
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Cochlea :  
The bony cochlea is a coiled tube lying in front of the vestibule and has 
an external appearance as that of snail. It spirals two and half turns about its 
central axis, the modilous, and has a height of 5mm. The apex of the cochlea 
faces laterally and forwards towards the upper part of the medial wall of the 
tympanic cavity, while the basal coil forms the bulge of the promontory. 
Bony spiral lamina is a thin shelf of bone arising from the modiolus that 
spirals upwards within the lumen of cochlea. The membranous spiral lamina 
extends from edge of bony spiral lamina to the outer wall of cochlea, thereby 
dividing each coil into the major portions, scala vestibuli superolaterally and 
scala tympani inferomedially. Between these two is the part of membranous 
labyrinth, scala media. 
 
Figure-2: cross section of cochlea. 
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The cochlea begins as an anterior periotic extension from the vestibule 
known as the scala vestibuli, that extension, is completely separated from scala 
tympani at that area by osseous spiral lamina, basilar membrane and spiral 
ligament. These structures inscribed a hook from the central axis of the 
cochlea and ultimately end at the inferolateral floor of the vestibule, adjacent 
to the otic capsule inferior to the oval window and posterior to the round 
window. The scala media end in this area in an osseous fossa known as 
cochlear recess of the vestibule. Into this recess fits a clusion of spiral ligament 
and the blind sac end of scala media known as the vestibular caecum.  
At the cochlear base, the scala vestibuli opens into the vestibule with 
the fenestra vestibuli and stapes footplate close by on the lateral wall of 
vestibule. The scala tympani is a blind end tube but has in its floor fenestra 
cochleae closed by the round widow. There is a communication between scala 
vestibuli and scala tympani and this is called helicotrema. 
Cochlear Duct (Scala Media) :  
It consists of a spirally arranged tube lying on the upper surface of the 
spiral lamina against the outer wall of the bony canal of the cochlea. The 
average length of the cochlea is around 34mm. Section of the cochlear duct is 
triangular with the floor formed by outer part of bony spiral lamina and all of 
the membranous spiral lamina and roof formed by sloping Reissner’s 
membrane  
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Lateral Wall of Cochlear Duct :  
It consists of spiral ligment, stria vascularis, spiral prominence and the 
cells of the outer sulcus. The spiral ligament is a thickened band of connective 
tissue that is firmly attached to lateral wall of the bony cochlear capsule. It 
provides support and points an anchorage for both Reissener’s membrane and 
basilar membrane and is thought to be the main source of perilymph. The stria 
vascularis is highly differentiated metabolically active tissue. The 
endocochlear potential of +80 to +100v generated by stria vascularis. The stria 
is also believed to be the source of endolymph.  
Roof of Cochlear Duct :  
The vestibular wall of cochlear duct is formed by Reissener’s 
membrane. It extends obliquely between the vestibular crest of spiral ligament 
and the spiral limbus and separates scala vestibuli from scala media. Its 
endolymphatic surface consists of a layer of epithelial cells and perilymphatic 
surface, a layer of connective tissue cells. The epithelial cells are attached to 
each other by tight junctions, that prevents the paracellular passage of 
molecules but is permeable to water. 
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Floor of Cochlear Duct :  
The tympanic wall of cochlear duct is formed by basilar membrane and 
spiral limbus. It is largely acellular and consists, primarily of a middle layer of 
radially oriented filaments that are continuous with the supporting bundle of 
spiral ligament and spiral limbus. 
 The basilar membrane play an important role in mechanical analysis 
and spatial representation of the sound. The elasticity of basilar membrane 
decreases hundred fold from its basal to apical ends. Because of this variation 
in stiffness, the location of the maximal deflection of the basal membrane 
varies frequency. High frequencies cause maximal deflections at the stiff basal 
end and low frequencies occur progressively towards the more elastic apex.  
The spiral limbus consists of thickened connective tissue and is firmly 
attached to the osseous spiral lamina on which it rests.The spiral limbus 
provides support for tectorial and basilar membranes.  
Organ of Corti :  
Attached to the upper surface of basilar membrane extending into the 
scala media is a highly specialized portion of the cochlear duct, the organ of 
corti. It consists of two types of cells, sensory cells which transduce sound 
energy into general activity and supporting cells which provide support to 
organ of corti. The afferent fibres of auditory nerve and efferent fibres of the 
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olivocochlear bundle enter the organ of corti from underneath the basilar 
membrane and innervate the sensory cells. 
The sensory cells consists of inner and outer hair cells, so named 
because of the sensory hair (Stereocilia) that extends from the upper surface 
and their relative proximity to the modiolus.  There are about 34000 inner hair 
cells and 12000 outer hair cells.  The inner hair cells are flask shaped. Its 
upper surface is covered with thick, rigid cuticle from which 3 to 4 straight or 
slightly curved parallel rows of stereocilia project. Actin filaments extends 
from surface to base of each hair ensuring it with rigidity and shape. The outer 
hair cells are cylindrical. Like the inner hair cells they have a cuticular plate, a 
small cuticle free surface with underlying basal body, and stereocilia which are 
arranged in rows according to height. The sterocilia of outer hair cells form 6 
to 7 parallel rows in the shape of V or W. 
 
Figure -3: organ of corti 
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The hair cells are supported in a rigid frame work of what is 
collectively called supporting cells. As one moves from the spiral limbus 
towards the spiral ligament, the supporting cells include the inner border cells, 
the inner pharyngeal cells, Hensen’s cells,Claudius cells, and the outer sulcus 
cells. The main structural support is provided by pillar cells and Dieter’s cells.  
There are number of fluid filled spaces enclosed within the organ of 
corti. This includes tunnel of corti between the pillar cells, Nuel space between 
the outer pillar cells and the first row of inner hair cells, the outer tunnel 
between the outer row of outer hair cells and inner row of Hensen’s cells and 
spaces that separate the outer hair cells. These spaces are filled with 
Cortilymph.  
Suspended above the organ of corti and connected to interdental cells of 
spiral limbus, is the tectorial membrane, which is completely acellular. It 
consists of transversely running filaments and has a gelatinous consistency.  
Innervation of the Cochlea:  
Cochlea is connected with brain stem by afferent and efferent nerves.  
Afferent Innervation :  
The auditory portion of VIII nerve provides the afferent innervation of 
the inner and outer hair cells. The cell bodies of cochlear nerve are located in 
the modiolus within the Rosenthal’s canal. Here they form spiral ganglion. 
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The axon of each ganglion cell extends centrally through longitudinal modular 
canal upto the cerebello pontine cistern synapse in the cochlear nucleus. The 
peripheral process ends as dendrite beneath the hair cells. 
Efferent Innervation :  
It is provided by olivocochlear bundle. The cell bodies of olivocochlear 
bundle are located in the brain stem within the superior olivary complex. The 
olivocochlear bundle is divided into medial and lateral components. 
 The medial division of olivocochlear bundle consists of myelinated 
fibres that originate from large cells in the medial part of superior olivary 
complex. Axons from superior olivary complex cross over to the other side of 
the brain just below the floor of the fourth ventricle and join the ipsilateral 
fibres. The ipsilateral and contralateral fibres travel peripherally within the 
vestibular nerve and join the cochlear nerve through corti’s anastamosis just 
distal to the sacuolar ganglion. 
  The lateral division of olivocochlear bundle consist of unmyelinated 
fibres which originate in small cell in lateral portion of superior olivary 
nucleus. These fibres follow the same course as does the medial division into 
organ of corti. 
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figure -4: Auditory pathway. 
Vascular Supply :  
The arterial supply to the cochlea is from two arteries that branch from 
common cochlear artery. These are  
i) Main cochlear which supplies the modiolous particularly at upper basal, 
middle and apical coils.  
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ii) Cochlear ramus of the vestibulocochlear artery, which supplies 1/4th of the 
basilar coil and modilous. Once within the modiolus the arteries branch to 
form an external and internal radiating arterioles. The external one travels 
within the interscalar septum to the lateral wall of the coil. The internal 
radiating arteriole supplies the medial wall of the coil and organ of corti. 
The venous drainage of inner ear is through the veins of vestibular and 
cochlear aqueducts. The primary drainage of cochlea is by anterior and 
posterior spiral veins. The posterior vein drains the inferomedial aspect of 
cochlea mainly spiral ganglion, scala media and scala tympani. The anterior 
spiral vein drains the superolateral aspect mainly scala vestibuli and osseous 
spiral lamina. These veins enter the common modiolar vein which enters the 
vein of cochlear aqueduct, tributary of inferior petrosal sinus. 
Physiology :  
There are two essential physiological process in cochlea namely 
transmission and transduction. Transmission is the transfer of acoustic energy 
from oval window to hair cells. While transduction is the conversion of sound 
energy pattern in organ of corti into action potential in the auditory nerve. 36. 
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Electrical Potentials Cochlea :  
Two main types of potentials have been identified the steady or resting 
potential and the superimposed QC voltage fluctuations due to acoustic 
stimulation.  
The resting potential in scala media is +80mv known as endolymphatic 
potential and hair cell has –80mv, So that there is potential difference of 
160mv between scala media and interior of hair cells.  
The cochlear microphonics is the main component and confers upon the 
cochlear potentials. It has two elements cochlear microphonics 1, which is 
oxygen dependent and cochlear microphonics 2, which is oxygen independent. 
Cochlear microphonics is generated at the hair cell tectorial membrane area by 
piezo electrical effect due to deformation by sound vibration of the hair or hair 
cell bodies.  
Cochlear Hydrodynamics :  
There is basic assumption underlying present day theories of hearing 
that cochlear fluids vibrate from window to window. These are called 
travelling waves. This wave appears at basal end of basilar membrane and 
moves until maximum is reached. Beyond this the amplitude falls rapidly and 
there is alteration in the phase of vibrations. The form of wave is independent 
of frequency but the region of maximum displacement of the basilar 
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membrane varies according to the frequency. High pitched sounds cause a 
short traveling wave, which does not extend beyond the basal turn.  
Middle and low frequencies produce the maximum displacement progressively 
nearer the apex as the frequency is lowered.  
Theories of Hearing :  
Helmholtz suggested that frequency analysis by the ear was due to the 
fact that, each pitch would cause resonant vibration of its own, in particular 
place on the basilar membrane. It was postulated with some support from 
anatomical observation that the length, mass and tension of the combined 
basilar membrane and the organ of corti varied progressively from base to the 
apex of the cochlea so as to form a series of tuned resonators. In fact damping, 
not resonance is the more conspicuous property of this complex system. 
Rutherford’s telephone hypothesis is that the basilar membrane vibrates 
uniformly in all its parts and that its amplitude represents the intensity of 
signal. Meanwhile he postulated that the frequency of signal is represented by 
the rate of firing of the auditory nerve fibres. This hypothesis simplifies the 
complexity of the nerve to a mere piece of wire and relegates to the CNS all 
problems relating to frequency analysis. Such a view has never been 
acceptable in the light of what is known as neurophysiology. The refractory 
period of nerve action would itself limit the upper frequency of the system to 
less than 1000 Hz. 
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Figure-5: representing different frequencies in cochlea. 
Weaver put forward “volley theory‟ which meets many of the 
requirements. It states that high frequency perception is due to stimulation of 
hair cells in basal turn only low frequency stimulate entire organ of corti and 
are represented in auditory nerve by nerve fibre responses which are directly 
synchronous with applied signal wave from.  
Between 400 and 5000Hz, groups of fibres fire asynchronously so that despite 
the limitations of the frequency of the signal is represented to the CNS by 
sequential firing the pairs, trios or quarters of fibres. There is presumed to be a 
gradual transition from one mode of action potential to the next as signal 
frequency is raised or lowered.  
Volley theory is supported by direct recording of action potentials in 
the auditory nerve and individual fibres. 
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PATHOGENESIS OF SENSORINEURAL HEARING LOSS IN 
DIABETICS :  
The three main theories in the pathogenesis of sensorineural hearing 
loss in diabetic patients are microangiopathy of cochlear vessels, neuropathy 
of auditory nerve and alteration in inner ear glucose levels.  
The angiopathy of the inner ear leads to deafness either by diminution 
of transport of nutrients through thickened capillary walls or by diminution of 
blood flow through narrowed vasculature. The primary diabetic neuropathy 
may be due to accumulation of sorbitol within the nervous tissue, the 
secondary neuropathy is due to decrease in the blood flow of vasa nervosum 
causing secondary degeneration of eighth cranial nerve. The inner ear utilizes 
glucose to produce energy and changes in the glucose concentration in the 
inner ear may alter hearing. 
Recently it is been recognized that diabetics with mitochondrial DNA 
abnormalities are associated with sensorineural hearing loss. The pathogenesis 
being disruption of energy production which thus compromises tissues with 
high metabolic energy requirements like labyrinth of the ear.  
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Histopathological changes seen in inner ear in diabeties mellitus :  
Microangiopathic changes with PAS positive precipitates in stria 
vascularis, internal auditory artery, modiolus, vasa nervosum of eighth nerve 
and spiral ligament. 
There was also demonstration of hemorrhage in endolymph and 
perilymph along with loss of hair cells, atrophy of spiral ganglion, 
demyelination of eighth nerve and degenerative changes in brain stem and 
cerebellum. 
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RETINAL VASCULAR ANATOMY 
The retina receives its nutrition from two discrete circulatory systems – 
the retinal blood vessels and the choroidal blood vessels both derived from the 
ophthalmic artery.40,41 The inner two-thirds of the human retina is nourished 
by four branch of the central retinal artery each supplying a quadrant of retina. 
The temporal branches arch around the macula and create a foveal avascular 
zone which is a 0.4 mm diameter, capillary free zone of pure cone 
photoreceptors.47,48  
Arteries and veins remain in the nerve fiber layer, while arterioles and 
venules extend into deeper layers of retina forming microvascular networks 
which vary from 3 layers at the posterior pole to one layer in the periphery 
Cilioretinal arteries, derived from posterior ciliary arteries, emanate from 
temporal rim of optic nerve head toward the macula. Because the only 
connection between retinal arterial and venous system is through the capillary 
network, no connection exist between the capillary beds derived from 
individual branch retinal arteries creating functional watershed zones. Retinal 
capillaries are 5-6 μm in diameter and consist of two layers – endothelial cells 
and a surrounding layer of pericytes. The pericyte to endothelial cell ratio is 
1:1 which is relatively high compared with elsewhere in CNS. The tight 
junctions between the  retinal capillary endothelial cells are the major 
component of inner blood retinal barrier. The retinal pericytes appear to be 
involved directly in the local control of retinal blood flow and may affect 
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endothelial cell proliferation. The branch retinal veins drain to central retinal 
vein. 
The choroid is supplied posteriorly by 10-20 short posterior ciliary 
branches. Majority of them give rise to choriocapillaries containing fenestrated 
endothelium supplying the outer third of retina. The choriocapillaries are 
functionally divided into lobules. The outer choroid is mainly a venous 
system, with the choriocapillaries connecting with an intermediate layer and 
finally with exterior choroidal veins. An important portion of outer blood 
retinal barrier consists of choriocapillary basement membrane, Bruch’s 
membrane and the intercellular junctions of the retinal pigment epithelium.42 
 
Figure -6: Normal fundus photograph 
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Figure -7: Normal histology of retinal capillaries 
PHYSIOLOGY 
Compared to the choroidal circulation which is a high flow, variable 
rate system, the retinal circulation is a lower flow, constant rate system 
supplying a highly metabolically active tissue. The works of Riva (1981) and 
Robinson (1986)43 showed that autoregulation maintains a constant retinal 
blood flow over a wide pressure range during ocular or systemic hypertension. 
Autoregulation depends upon many constituents of microenvironment 
viz. endothelium, pericytes, smooth muscle cells, extracellular matrix and the 
soluble vasoactive molecules. 
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VASCULAR PATHOLOGY IN DIABETIC RETINOPATHY 
1. Abnormal retinal haemodynamics correlate with abnormal visual 
function in diabetic retinopathy. Enlargement of FAZ correlates 
with degree of ischaemic maculopathy. In early stage of diabetes, 
capillary density and the size of FAZ correlate inversely with 
contrast sensitivity. 
2.  Total retinal blood flow is decreased in diabetics without diabetic 
retinopathy and increases as disease progresses prior to 
vasoproliferation. 
3. There is significant retinal auto-regulatory dysfunction in proportion 
to disease. 
MOLECULAR BASIS OF DIABETIC RETINOPATHY 
The retinal changes in patients with diabetes result from five 
fundamental processes: 
i. formation of retinal capillary micro aneurysms 
ii.The development of excessive vascular permeability 
iii. Vascular occlusion, 
iv.  The proliferation of new blood vessels and accompanying fibrous tissue on 
the surface of the retina and optic disc, and 
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v. The contraction of these fibrovascular proliferations and the vitreous. 
The clinicopathological lesions of diabetic retinopathy have been well 
classified. 
Although a multitude of pathogenic mechanisms have been proposed, 
the underlying dysfunctional biochemical and molecular pathways that lead to 
initiation and progression of DR still remains an enigma. Currently four major 
biochemical pathways have been hypothesized to explain the mechanism of 
diabetic eye diseases all starting initially from hyperglycaemia induced 
vascular injury.49 These mainly include: 
(i)  Enhanced glucose flux through the polyol pathway 
(ii)  Increased intracellular formation of advanced glycation end-products 
(AGE) 
(ii) Activation of protein kinase C (PKC) isoforms, and 
(iv)  Stimulation of hexosamine pathway 
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OPHTHALMOSCOPIC FEATURES OF DIABETIC RETINOPATHY45 
Microaneurysms 
Microaneurysms are localized out-pouchings, mainly saccular, of the 
capillary wall that may form either by focal dilatation of the capillary wall 
where pericytes are absent, or by fusion of two arms of a capillary loop. Most 
develop in the inner capillary plexus (inner nuclear layer) frequently in 
relation to areas of capillary non perfusion. Loss of pericytes may also lead to 
endothelial cell proliferation with the formation of ‘cellular’ microaneurysms. 
Microaneurysms may leak plasma constituents into the retina as a result of 
breakdown in the blood–retinal barrier, or become thrombosed. 
 
Figure -8: microaneurysms of retinal capillaries 
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Retinal haemorrhages 
1.  Retinal nerve fibre layer haemorrhages arise from the larger 
superficial precapillary arterioles and are flame-shaped because of the 
architecture of the retinal nerve fibres 
2.  Intraretinal haemorrhages arise from the venous end of capillaries red 
‘dot/blot’ shape, located in the compact middle layers of the retina. 
3.  Deeper dark round haemorrhages due to haemorrhagic retinal infarct 
located within the middle retinal layers. 
Exudates 
Exudates, sometimes termed ‘hard’ exudates to distinguish from the 
older term of ‘soft’ exudates for cotton wool spots, are caused by chronic 
localized retinal oedema developing at the junction of normal and oedematous 
retina. They are composed of  lipoprotein and lipid-filled macrophages located 
mainly within the outer plexiform layer. Hyperlipidaemia is a risk factor for of 
exudate formation. 
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Figure -9: hard  exudates. 
Cotton wool spots 
Cotton wool spots are composed of accumulations of neuronal debris 
within the nerve fibre layer, resulting from disruption of nerve axons. On light 
microscopy appear as globular structures in the nerve fibre layer .The swollen 
ends of which are known as cytoid bodies. 
 
Figure -10: cotton wool spots. 
48 
 
Venous changes 
Venous anomalies seen in ischaemia consist of generalized dilatation 
and tortuosity, ‘looping’, ‘beading’ and ‘sausage-like’ segmentation. The 
extent of the retinal area exhibiting venous changes is an important predictor 
for the likelihood of developing 
proliferative disease. 
 
Figure -11: venous dilatation. 
Intraretinal microvascular abnormalities (IRMA) are arteriolar-venular 
shunts seen adjacent to areas of marked capillary hypoperfusion. They bypass 
the occluded capillary bed and run from retinal arterioles to venules. 
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Arterial changes: Subtle retinal arteriolar dilatation may be an early marker 
of ischaemic dysfunction. When significant ischaemia is present a variety of 
features are seen which include peripheral narrowing, silver-wiring and 
obliteration similar to the late appearance following a branch retinal artery 
occlusion. 
Risk factors 
•  Duration of diabetes is the most important risk factor. In patients 
diagnosed with diabetes before the age of 30 years, the incidence of DR is 
50% after 10 years, and after 30 years its about 90%. DR rarely develops 
within 5 years of the onset of diabetes or before puberty, but about 5% of 
type 2 diabetics have DR at presentation. 
•  Poor control of diabetes. It has been shown that tight blood glucose 
control, particularly when instituted early, can prevent or delay the onset & 
development or progression of DR.  However, a sudden improvement in 
control may be associated with progression of retinopathy in the near term. 
Type 1 diabetic patients appear to obtain greater benefit from good control 
than type 2. Raised HbA1c is associated with an increased risk of 
proliferative disease. 
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•  Pregnancy is sometimes associated with rapid progression of DR. 
Predicating factors include greater pre-pregnancy severity of retinopathy, 
poor pre-pregnancy control of diabetes, control exerted too rapidly during 
the early stages of pregnancy, and pre-eclampsia. The risk of progression is 
related to the severity of DR in the first trimester. If substantial DR is 
present, frequency of review should reflect individual risk, and can be up to 
monthly. Diabetic macular oedema usually resolves spontaneously after 
pregnancy and need not be treated if it develops in later pregnancy. 
•  Hypertension, which is very common in patients with type 2 diabetes, 
should be rigorously controlled (<140/80 mmHg). Tight control appears to 
be particularly beneficial in type 2 diabetics with maculopathy. 
Cardiovascular disease and previous stroke are also predictive. 
•  Nephropathy, if severe, is associated with worsening of DR. Conversely, 
treatment of renal disease (e.g. renal transplantation) may be associated 
with improvement of retinopathy and a better response to 
photocoagulation. 
•  Other risk factors include hyperlipidaemia, smoking, cataract surgery, 
obesity and anaemia. 
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Early Treatment Diabetic Retinopathy Study Group [ETDRS]:53 
A) Non-proliferative Diabetic Retinopathy [NPDR] :- 
1) Minimal NPDR :- Presence of microaneurysms only 
2) Mild NPDR:- Microaneurysms + one or more of the following Intra-retinal 
haemorrhages, Hard exudates away from the macula, Cotton wool spots 
(CWS). 
3) Moderate NPDR :- Microaneurysms / Hemorrhages in at least one 
quadrant+one or more of the following:- 
Cotton wool spots, Intra-retinal microvascular abnormalities (IRMA) 
Venous beading. 
4) Severe NPDR :- Any one of the following (4-2-1 rule) Intra-retinal 
hemorrhages – severe, in 4 quadrants  
Venous beading in 2 quadrants 
Moderately severe intra-retinal microvascular abnormalities(IRMA) in 1 
quadrant. 
5) Very severe NPDR :- Any two of the following :- 
Intra-retinal hemorrhages-severe, in 4 quadrants venous beading in 2 
quadrants. 
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Moderately severe intra-retinal microvascular abnormalities in 1 quadrant. 
B) Proliferative Diabetic Retinopathy [PDR] :- 
1) Early PDR :- One or more of the following :- 
NVD < ¼ disc diameter [DD] 
NVE without hemorrhage 
Pre-retinal or vitreous hemorrhage and NVE < ½ DD without hemorrhage. 
2) High risk PDR :- One or more of the following :- 
NVD >1/4 DD 
NVD with hemorrhage. 
NVE >1/2 DD with hemorrhage. 
 
Figure -12: Mild NPDR. 
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Figure -13 a.: moderate NPDR. 
 
Figure -13 b.: moderate NPDR 
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Figure -14: severe NPDR 
 
Figure -15: PDR 
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Clinically Significant Macular Edema (CSME) 
 As defined by the Early Treatment Diabetic Retinopathy Study 
(ETDRS) includes any one of these lesions. 
1.  Retinal thickening at or within 500 μm at the centre of the macula. 
2.  Hard exudates at or within 500 μm of the centre of the macula, if there 
is thickening of the adjacent retina. 
3.  An area or areas of retinal thickening at least one disc area in size, 
atleast a part of which is within 1 disc diameter of the centre of the 
macula. 
 
Figure -16: CSME. 
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Diabetic maculopathy is the most common cause of visual loss in 
nonproliferative diabetic retinopathy. 
The various forms of diabetic maculopathy based on FFA include: 
1.  Focal exudative maculopathy: There is focal leakage with hard 
exudates, sparing the foveal center, and the prognosis is good. 
2.  Diffuse exudative maculopathy: There is diffuse macular oedema and 
the prognosis is often poor. 
3. Ischaemic maculopathy: There are extensive areas of macular 
nonperfusion, soft exudates and large deep retinal hemorrhages with 
retinal thickening seen on ophthalmoscopy. There is reduced visual 
acuity with a relatively normal appearance of the fovea. 
4.  Mixed maculopathy: characterized by features of both ischaemia and 
exudation. 
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Figure -17: fundus fluorescein angiograph with macular edema. 
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MATERIAL  & METHOD 
METHOD: 
A sample of 92 subjects are selected by blind randomization & divided 
into cases & controls of 46 individuals in each. Detailed clinical examination 
of ear & eye is performed, including tuning fork tests fundoscopy & subjected 
to investigations. The data collected from these tests & investigations are 
subjected to appropriate statistical tests to arrive suitable conclusions. 
SAMPLE SIZE: 
· The sample size was determined by using G*Power software 3.1 
Version with a power of 95 % and confidence interval level 95 %.  
· The estimated sample size was 42 in each group.  
· Considering the attrition rate 10 %, a total of 46 samples in each group 
was planned for the study.  
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MATERIAL: 
CASES: - A sample of 46 patients of diabetes mellitus of both sexes, selected 
based on following inclusion criteria. 
CONTROLS: - a sample of 46 non-diabetic subjects of both sexes, selected 
based on following inclusion criteria. 
INCLUSION CRITERIA FOR CASES: 
1. Age 18-55.  
2. Known diabetic patients attending diabetology clinic. 
3. Patients with no history of ototoxic drug consumption in past. 
4. Subjects with no history of any ear disease or ear surgeries in past. 
5. Patients without noise induced hearing loss as per PTA. (dip at 
4000Hz). 
6. Diabetic patients without any pre existing co-morbidities which are 
likely to affect hearing. (hyperlipidemia, hypertension) 
7. Diabetic patients without pre existing retinopathy. 
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INCLUSION CRITERIA FOR CONTROLS: 
1. Age 18-55 
2. Normoglycemic. 
3. Subjects with no history of ototoxic drug consumption in past. 
4. Subjects with no history of any ear disease or ear surgeries in past. 
5. Subjects without noise induced hearing loss. 
6. Normal individuals without any pre existing co-morbidities which are 
likely to affect hearing. (hyperlipidemia, hypertension) 
7. Normal individuals without pre existing retinopathy. 
EXCLUSION CRITERIA: 
1. Age <18 & >55. 
2. H/o prolonged exposure to noise (e.g. Industrial workers). 
3. H/o ear discharge, perforated tympanic membrane or any chronic ear 
disease & ear surgeries in the past. 
4. H/o intake of ototoxic drugs intake. 
5. H/o pre existing co-morbidities which are likely to affect hearing. 
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STATISTICAL TOOLS: 
· The collected data was analysed with SPSS 16.0 version. 
· To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and for 
continuous variables the mean and S.D will used. 
·  To find the significance difference between the Independent groups 
(Cases & Controls) Unpaired t-test will be used. 
· For age wise comparison One way ANOVA  will be used. 
· To assess the relationship between the variables Pearson’s Correlation 
will be used. 
· To find the significance in the categorical data Chi-Square test will be 
used.  
· In all the above statistical tools the P value ≤ .05 is considered as 
significant level. 
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PROCEDURE:  
· PURE TONE AUDIOMETRY (PTA) 
The patient should be visible to the tester and respond by raising his 
finger after hearing stimulus. No visible or tactile clues should be given 
to patient which may suggest the presentation of auditory stimulus. The 
test should be performed in sound proof room. 
The duration of presentation of stimulus should be 1-3 seconds. 
Rhythmic presentations should be avoided which may lead to the patients 
anticipating near threshold levels and likewise regular automatic switching 
should not be used. Unduly long interval between thresholds may lead to poor 
measured thresholds. Initially patient is familiarized to the sound by presenting 
a tone above the clinical hearing level and checking that the patient indicates 
whole duration of stimulus by changing the length of stimulus. 
The threshold of hearing for a pure tone is the maximum tone that can 
elicit a response from at least 50% of the individual presentations. The test 
starts with better ear in the following order: 1KHz, 2KHz, 4KHz, 8KHz, 
500Hz and 250Hz. If there is difference in the air conduction threshold 
exceeding 40dB at any frequency, masking should be used.  
Bone conduction threshold are obtained similarly, as for air conduction 
but sound stimulus is given by bone vibrator placed on mastoid process. Care 
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is taken to remove intervening hair. Measurements are restricted to frequencies 
up to 4000Hz only. 
Air conduction thresholds in the right and left ears were marked by ‘O’ 
and ‘X’ respectively. Bone conduction threshold is obtained by using bone 
vibrator placed on the skin over mastoid process and assessed to a maxium of 
4000Hz. 
It is represented by symbols ‘[‘ and ‘]’ for right and left ear 
respectively. Masking is employed when the difference in right and left 
unmasked air conduction threshold is 40dB or more.  
The hearing threshold grading is given by:  
1. 0-25dB –normal hearing  
2. 26-40 dB –mild hearing loss  
3. 41-55dB –moderate hearing loss  
4. 56-70dB –moderately severe hearing loss  
5. 71-90dB-severe hearing loss  
6. >90dB- profound hearing loss 
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FUNDOSCOPY: 
Fundoscopy consists exclusively of inspection. One looks through 
the ophthalmoscope, which is simply a light with various optical 
modifications, including lenses. The ophthalmoscope illuminates the retina 
through the normal iris defect  that is the pupil. Light rays forming the image 
of the retina re-emerge through the pupil. The viewing aperture (window) of 
the ophthalmoscope contains a lens that modifies light rays to assist the user. 
In the procedure, one looks at structures lying in the innermost aspect of the 
globe, collectively known as the eyegrounds: retina, retinal blood vessels, 
optic nerve head (disc), and to a limited degree, subjacent choroid. The pupil is 
frequently dilated pharmacologically to render retinal inspection easier, and 
for examination of the macula. One paralyzes the pupilloconstrictor muscle of 
the iris with nonabsorbable, short-acting topical parasympatholytic 
drugs, resulting in a larger pupillary aperture. 
VISION TEST: 
The goal in testing central visual acuity is to determine the best possible 
visual acuity in each eye. In most instances, either a standard printed Snellen 
eye chart is used with the patient 20 feet (6 m) away or a reading card with a 
reduced eye chart is used at 14 inches (35 cm). One eye at a time is tested with 
the fellow eye occluded. If distance spectacles are used by the patient (i.e., 
"the glasses you drive and walk around with"), they should be worn during 
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testing. If the reduced visual acuity card is being used at 14 inches, the patient 
over 40 years of age should wear reading glasses or bifocals ("the glasses you 
read with"). Should the patient's glasses not be available, an approximation of 
best corrected visual acuity can be obtained with the use of a pinhole held as 
close to the eye as possible while testing vision.  A much easier and faster 
technique is to instruct the patient to "read the smallest line that you can see." 
Often, this will result in the patient going right to the 20/20 line and reading it 
correctly. 
Blood investigations:  
The patient’s blood was assigned for the routine blood investigations as 
haemoglobin, total count, differential count and platelets to rule out anaemia, 
leukaemia and other disorders. Fasting and post prandial blood sugar levels 
were measured in the central laboratory attached to our hospital. To assess the 
diabetic control of the patient in the last 3 months HbA1c was done and graded 
as: 
· < 7% -good control  
· 7-8%- moderate control  
· >8%- poor control  
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The renal parameters like blood urea (25-45mg/dl) and serum creatinine 
(0.7-1.5mg/dl) were also taken in to account. Routine urine analysis was done 
to monitor microalbuminuria and ketone bodies.  
In our study the cut off values for cases and controls were as follows: 
1)  HbA1C levels between 4.5 and 5.7% (for controls only) 
2)  Total serum cholesterol ≤ 200 mg/dl 
3)  LDL ≤ 130 mg/dl 
4)  HDL ≤ 55 mg/dl for males and between 45 and 65 mg/dl for females 
5)  Triglycerides ≤ 160 mg/dl 
6)  Creatinine: between 0.3 and 1.3 mg/dl 
7)  Proteinuria (measured in 24-hour urine volume) ≤ 0.15 g 
8)  High blood pressure was defined as systolic pressure > 140 mmHg 
and/or diastolic pressure >110 mmHg. 
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RESULT 
 The occurrences of sensory neural hearing loss and retinopathy among 
diabetic patients was compared with those of non-diabetics under the 
following parameters: 
1. Age of individuals. 
2. Sex of individuals. 
3. Retinopathy among cases and controls. 
4. SNHL among cases and controls. 
5. Incidence of sensory neural hearing loss either sudden or gradual onset. 
6. Vision acuity among cases and controls. 
7. Retinopathy versus duration of disease. 
8. SNHL versus duration of disease. 
9. HbA1c versus SNHL. 
10.HbA1c versus retinopathy. 
11. Correlation between SNHL and retinopathy. 
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AGE DISTRIBUTION:  
TABLE -1. 
AGE DISTRIBUTION: 
  
CC 
Total 
CASES CONTROLS 
Age 
range 
18- 30 yrs Count 3 11 14 
 % within CC 6.5% 23.9% 15.2% 
31 - 40 yrs Count 8 13 21 
 % within CC 17.4% 28.3% 22.8% 
41 - 50 yrs Count 21 14 35 
 % within CC 45.7% 30.4% 38.0% 
51- 55 yrs Count 14 8 22 
 % within CC 30.4% 17.4% 23.9% 
Total Count 46 46 92 
% within CC 100.0% 100.0% 100.0% 
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N Mean 
Std. 
Deviation 
AGE CASES 46 45.22 7.922 
CONTROLS 46 39.78 10.035 
 
Majority of cases that is 45.7% and 30.4% were in the age group of 41-
50 years & 51- 55years respectively. Whereas controls were almost equally 
divided among different age groups. Mean of age distribution among cases is 
45.22 years to that of controls its 39.78years. 
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SEX DISTRIBUTION: 
TABLE -2: SNHL V/S GENDER AMONG CASES 
SNHL V/S GENDER AMONG 
CASES 
GENDER 
Total 
Female Male 
HEARINGLOSS No HL Count 1 4 5 
 % within 
GENDER 
4.3% 17.4% 10.9% 
Mild Count 5 7 12 
 % within 
GENDER 
21.7% 30.4% 26.1% 
Moderate Count 12 7 19 
 % within 
GENDER 
52.2% 30.4% 41.3% 
Severe Count 2 5 7 
 % within 
GENDER 
8.7% 21.7% 15.2% 
PF Count 3 0 3 
 % within 
GENDER 
13.0% 0.0% 6.5% 
Total Count 23 23 46 
% within 
GENDER 
100.0% 100.0% 100.0% 
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41.3% of cases with SNHL were men & 47.8% cases with SNHL were 
women. 
There is no statistical significance between gender and SNHL with P 
value – 0.102. 
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TABLE-3: RETINOPATHY V/S GENDER AMONG CASES. 
RETINOPATHY V/S GENDER IN 
CASES 
GENDER 
Total 
Female Male 
RETINOPATHY NR Count 5 7 12 
 % within 
GENDER 
21.7% 30.4% 26.1% 
G 1 Count 6 6 12 
 % within 
GENDER 
26.1% 26.1% 26.1% 
G 2 Count 6 4 10 
 % within 
GENDER 
26.1% 17.4% 21.7% 
G 3 Count 1 3 4 
 % within 
GENDER 
4.3% 13.0% 8.7% 
G 4 Count 2 1 3 
 % within 
GENDER 
8.7% 4.3% 6.5% 
PDR 
G 1 
Count 2 1 3 
 % within 
GENDER 
8.7% 4.3% 6.5% 
PDR 
G2 
Count 1 1 2 
 % within 
GENDER 
4.3% 4.3% 4.3% 
Total Count 23 23 46 
% within 
GENDER 
100.0% 100.0% 100.0% 
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39.1% of cases with retinopathy were women & 34.78% of cases with 
retinopathy were men. 
There is no statistical significance between gender and retinopathy with 
P value – 0.879. 
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RETINOPATHY AMONG CASES & CONTROLS:  
TABLE -4. 
  
CC 
Total 
CASES CONTROLS 
RETINOPATHY NR Count 12 38 50 
 % within CC 26.1% 82.6% 54.3% 
G 1 Count 12 5 17 
 % within CC 26.1% 10.9% 18.5% 
G 2 Count 10 3 13 
 % within CC 21.7% 6.5% 14.1% 
G 3 Count 4 0 4 
 % within CC 8.7% 0.0% 4.3% 
G 4 Count 3 0 3 
 % within CC 6.5% 0.0% 3.3% 
PDR 
G 1 
Count 3 0 3 
 % within CC 6.5% 0.0% 3.3% 
PDR 
G2 
Count 2 0 2 
 % within CC 4.3% 0.0% 2.2% 
Total Count 46 46 92 
% within CC 100.0% 100.0% 100.0% 
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73.9% of cases had retinopathy when compared to controls only 17.4% 
of them had retinopathy. 
Its statistically highly significant that cases are more prone for 
retinopathy than controls with P value :- <0.001. 
Among 73.9% of cases with retinopathy 63% (29 cases) of them had 
NPDR & 10.8% (5 cases) of them had PDR. 
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SNHL AMONG CASES & CONTROLS: Table -5. 
  
CC 
Total 
CASES CONTROLS 
HEARINGLOSS No HL Count 5 32 37 
 % within 
CC 
10.9% 69.6% 40.2% 
Mild Count 12 7 19 
 % within 
CC 
26.1% 15.2% 20.7% 
Moderate Count 19 5 24 
 % within 
CC 
41.3% 10.9% 26.1% 
Severe Count 7 2 9 
 % within 
CC 
15.2% 4.3% 9.8% 
PF Count 3 0 3 
 % within 
CC 
6.5% 0.0% 3.3% 
Total Count 46 46 92 
% within 
CC 
100.0% 100.0% 100.0% 
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89.1 % (41 cases) of cases had SNHL than compared to 30.4 % (14 
controls) of controls who had SNHL.  
Its statistically highly significant that cases are more prone for SNHL 
than controls with P value :- <0.001. 
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INCIDENCE OF HEARING LOSS: 
 In our study of 46 cases, 41 cases had SNHL of which 2 had sudden 
SNHL. Among the 46 controls 14 of them had SNHL and none had sudden 
SNHL. 
ONSET OF SNHL: TABLE -6 
  
CC 
Total 
CASES CONTROLS 
TYPE 
OF 
HL 
Gradual Count 39 14 53 
 % within CC 84.8% 30.4% 57.6% 
Sudden Count 2 0 2 
 % within CC 4.3% 0.0% 2.2% 
No HL Count 5 32 37 
 % within CC 10.9% 69.6% 40.2% 
Total Count 46 46 92 
% within CC 100.0% 100.0% 100.0% 
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Incidence of SNHL was 89.1% (41 cases) among the cases, when 
compared to 30.4% among controls.  
4.3% of cases had sudden onset SNHL and 84.8% had gradual SNHL. 
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VISUAL ACUITY AMONG CASES & CONTROLS:  
TABLE -7 
  
CC 
Total 
CASES CONTROLS 
VISION 
TEST 
6/18 Count 10 5 15 
 % within CC 21.7% 10.9% 16.3% 
6/24 Count 6 0 6 
 % within CC 13.0% 0.0% 6.5% 
6/36 Count 3 0 3 
 % within CC 6.5% 0.0% 3.3% 
6/6 Count 7 20 27 
 % within CC 15.2% 43.5% 29.3% 
6/9 Count 20 21 41 
 % within CC 43.5% 45.7% 44.6% 
Total Count 46 46 92 
% within CC 100.0% 100.0% 100.0% 
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84.8 % (39 cases) of cases had vision acuity below 6/6 than compared to 56.5 
% (26 controls) of controls who vision below normal. 
It’s statistically highly significant that cases are more prone for SNHL than 
controls with P value :- <0.002. 
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RETINOPATHY VERSUS DURATION OF DIABETES MELLITUS:  
TABLE -8 
  
Duration of DM range 
Total Upto 2 
yrs 
2 - 4 yrs 
4 - 6 
yrs 
Above 6 
yrs 
R
ET
IN
O
PA
TH
Y
 NR Count 9 2 1 0  112 
% within 
Drange 
60.0% 16.7% 10.0% 0.0% 26.1% 
G 1 Count 5 6 1 0 12 
% within 
Drange 
33.3% 50.0% 10.0% 0.0% 26.1% 
G 2 Count 1 3 6 0 10 
% within 
Drange 
6.7% 25.0% 60.0% 0.0% 21.7% 
G 3 Count 0 1 1 2 4 
% within 
Drange 
0.0% 8.3% 10.0% 22.2% 8.7% 
G 4 Count 0 0 0 3 3 
% within 
Drange 
0.0% 0.0% 0.0% 33.3% 6.5% 
PDR 
G 1 
Count 0 0 1 2 3 
% within 
Drange 
0.0% 0.0% 10.0% 22.2% 6.5% 
PDR 
G2 
Count 0 0 0 2 2 
% within 
Drange 
0.0% 0.0% 0.0% 22.2% 4.3% 
Total Count 15 12 10 9 46 
% within 
Drange 
100.0% 100.0% 100.0% 100.0% 100.0% 
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73.9 % (34 cases) of cases have retinopathy of varied severity. 
For all cases with duration of diabetes mellitus >2years 60.8% (28 
cases) had retinopathy than compared to those having diabetes mellitus 
<2years only 13.0% (6 cases) of them had retinopathy. 
4 of 5 cases with PDR had duration of diabetes mellitus >6years. 
Its statistically highly significant that cases with longer duration of 
diabetes mellitus have more severe retinopathy with P value:- <0.001. 
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SNHL VERSUS DURATION OF DIABETES MELLITUS: table -9. 
  
Duration of DM range 
Total Upto 2 
yrs 
2 - 4 
yrs 
4 - 6 
yrs 
Above 6 
yrs 
H
EA
R
IN
G
LO
SS
 No HL Count 4 1 0 0 5 
% 
within 
Drange 
26.7% 8.3% 0.0% 0.0% 10.9% 
Mild Count 9 3 0 0 12 
% 
within 
Drange 
60.0% 25.0% 0.0% 0.0% 26.1% 
Modera
te 
Count 2 8 9 0 19 
% 
within 
Drange 
13.3% 66.7% 90.0% 0.0% 41.3% 
Severe Count 0 0 1 6 7 
% 
within 
Drange 
0.0% 0.0% 10.0% 66.7% 15.2% 
PF Count 0 0 0 3 3 
% 
within 
Drange 
0.0% 0.0% 0.0% 33.3% 6.5% 
Total Count 15 12 10 9 46 
% 
within 
Drange 
100.0% 100.0% 100.0% 100.0% 100.0% 
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89.1% (41 cases) of cases have SNHL of varied severity.  
For all cases with duration of diabetes mellitus >2years 65.2% (30 
cases) had SNHL than compared to those having diabetes mellitus <2years 
only 23.9% (11 cases) of them had SNHL. 
Its statistically highly significant that cases with longer duration of 
diabetes mellitus have more severe SNHL with P value: - <0.001. 
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HbA1C VERSUS SNHL:  
TABLE -10 
CASES 
HEARINGLOSS 
Total 
N
o 
H
L
 
M
ild
 
M
od
er
at
e 
Se
ve
re
 
PF
 
H
B
A
1C
R
A
N
G
E <
 
7 
Count 1 2 0 0 0 3 
% within 
HEARING
LOSS 
20.0% 16.7% 0.0% 0.0% 0.0% 6.5% 
7
 
- 
8 
Count 3 9 10 0 0 22 
% within 
HEARING
LOSS 
60.0% 75.0% 52.6% 0.0% 0.0% 47.8% 
>
 
8 
Count 1 1 9 7 3 21 
% within 
HEARING
LOSS 
20.0% 8.3% 47.4% 100.0
% 
100.0
% 
45.7% 
Total Count 5 12 19 7 3 46 
% within 
HEARING
LOSS 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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Among all the cases having HbA1C >7 about 84.7% (39 cases) of them 
had SNHL. Only 4.3% of cases having HbA1C <7 had SNHL & that too mild. 
 63 % (29 cases) of cases had SNHL >41 dB of which 41.35% (19 
cases) of cases had HbA1C LEVELS >8. 
Its statistically highly significant that cases with poor glycaemia control 
(higher HbA1C levels) have more severe SNHL with P value: - <0.003. 
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HbA1C VERSUS RETINOPATHY: 
TABLE -11 
  
RETINOPATHY 
Total NR G 1 G 2 G 3 G 4 
PDR 
G 1 
PDR 
G2 
H
B
A
1C
R
A
N
G
E <
 
7 
Count 2 1 0 0 0 0 0 3 
% within 
RETINOPA
THY 
16.7
% 
8.3% 0.0% 0.0% 0.0% 0.0% 0.0% 6.5% 
7
 
- 
8 
Count 9 9 4 0 0 0 0 22 
% within 
RETINOPA
THY 
75.0
% 
75.0
% 
40.0
% 
0.0% 0.0% 0.0% 0.0% 47.8
% 
>
 
8 
Count 1 2 6 4 3 3 2 21 
% within 
RETINOPA
THY 
8.3% 16.7
% 
60.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
45.7
% 
Total Count 12 12 10 4 3 3 2 46 
% within 
RETINOPA
THY 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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Among all the cases having HbA1C >7 about 71.7% (33 cases) of them 
had retinopathy. Only 2.1% (1 case) of cases having HbA1C <7 had 
retinopathy & that too grade 1 NPDR. 
45.7% (21 cases) cases having HbA1C >8 about 43.47% (20 cases) of 
them had retinopathy. 10.8% (5 cases) of cases had PDR & all of them had 
HbA1C >8. 
Its statistically highly significant that cases with poor glycaemia control 
(higher HbA1C levels) have more severe retinopathy with P value: - <0.008. 
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CORRELATION BETWEEN SNHL AND RETINOPATY:  
TABLE -12. 
CASES 
HEARINGLOSS 
Total No 
HL Mild 
Modera
te 
Sever
e PF 
*R
ET
IN
O
PA
TH
Y
 NR Count 5 5 2 0 0 12 
 % within 
HEARINGLO
SS 
100.0
% 
41.7
% 
10.5% 0.0% 0.0% 26.1
% 
G 1 Count 0 7 5 0 0 12 
 % within 
HEARINGLO
SS 
0.0% 58.3
% 
26.3% 0.0% 0.0% 26.1
% 
G 2 Count 0 0 9 1 0 10 
 % within 
HEARINGLO
SS 
0.0% 0.0% 47.4% 14.3
% 
0.0% 21.7
% 
G 3 Count 0 0 2 2 0 4 
 % within 
HEARINGLO
SS 
0.0% 0.0% 10.5% 28.6
% 
0.0% 8.7% 
G 4 Count 0 0 0 1 2 3 
 % within 
HEARINGLO
SS 
0.0% 0.0% 0.0% 14.3
% 
66.7
% 
6.5% 
PD
R G 
1 
Count 0 0 1 1 1 3 
 % within 
HEARINGLO
SS 
0.0% 0.0% 5.3% 14.3
% 
33.3
% 
6.5% 
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PD
R 
G2 
Count 0 0 0 2 0 2 
 % within 
HEARINGLO
SS 
0.0% 0.0% 0.0% 28.6% 0.0% 4.3% 
Total Count 5 12 19 7 3 46 
% within 
HEARINGLO
SS 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
 
47.8% (22 cases) of cases had SNHL >41dB (>/=moderate SNHL) and 
these same cases had retinopathy of grade 2 NPDR or higher severity of 
retinopathy. 
Its statistically highly significant that diabetics (cases) with greater 
SNHL have more severe retinopathy with P value: - <0.001. 
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Unlike in cases there is no correlation between SNHL & retinopathy 
among controls. 
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DISCUSSION 
The present study was conducted in Govt. Stanley medical college and 
hospital Chennai from 1st August 2014 to 31th July 2015(12 months). 46 
cases of diabetes mellitus patients attending diabetology & ENT clinic were 
randomly selected according to inclusion criteria and 46 non-diabetics were 
randomly selected grouped as controls. These selected cases and controls were 
assessed for having sensorineural hearing loss and retinopathy. 
Also they were assessed based on: 
1. Age distribution. 
2. Sex distribution. 
3. Retinopathy, SNHL & vision acuity among cases and controls. 
4. Incidence of disease.  
4. Retinopathy & SNHL with respect to duration of disease. 
5. Retinopathy and SNHL with respect to disease control. 
6. Correlation between SNHL and retinopathy among diabetics. 
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AGE DISTRIBUTION: 
Review of literature shows that there is no correlation between age of 
the patient and occurrences of SNHL and retinopathy among diabetics stated 
as per by Cullen-R2 & Kurien-M22.  
Similarly no correlation was found in our study between age of the 
diabetics and its complications such as retinopathy and SNHL. 
Mean age distribution among cases is 45.22 years to that of controls its 
39.78years. 
SEX DISTRIBUTION: 
 No studies till date have compared the hearing thresholds and 
retinopathy between diabetic men and women. 
Our findings confirm with that of Nakaganvi et al.,46 with no statistical 
significance between gender and disease. 
41.3% of cases with SNHL were men & 47.8% cases with SNHL were 
women with P value – 0.102. 
39.1% of cases with retinopathy were women & 34.78% of cases with 
retinopathy were men with P value – 0.879. 
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RELATIONSHIP BETWEEN RETINOPATHY, SNHL & VISION 
ACUITY AMONG CASES & CONTROL: 
 In our study 73.9% of cases had retinopathy when compared to 17.4% 
of controls with significant P value. 89% of cases had sensory neural hearing 
loss than that of 30.4% of SNHL among controls. 
84.3% of cases had below normal visual acuity. 
Confirming that diabetics are more prone for SNHL and retinopathy7 
with poor vision stated as per P A Wachyam4, Gareth William, John C5. 
INCIDENCE OF SENSORY NEURAL HEARING LOSS (SUDDEN OR 
GRADUAL): 
 Most of the recent literatures in recent times have supported the 
association of SNHL with DM. 
In our study of 46 cases 89.1% of them had SNHL when compared to 
30.4% among controls. 4.3% of cases had sudden onset SNHL and 84.8% had 
gradual SNHL. The results are similar to that of Friedman18 and Aggarwal.19 
Sensory neural hearing loss is usually gradual but Shuen Fu54 in 2005 
reported 68 cases of sudden SNHL. 
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DURATION OF DISEASE WITH THAT OF RETINOPATHY & SNHL: 
 Some studies state that the hearing threshold increases with increase in 
duration of DM3,10 while some state that there is no relation between SNHL 
with duration.22,2 
In our study 73.9% of cases had retinopathy. Among these 60.8% cases 
with >2years of DM had retinopathy. Only 13% of cases with <2years of DM 
had retinopathy.  
About 39.1% cases of retinopathy had DM for >4 years. 4 out of 5 
cases of PDR had DM > 6 years. 
65.2% of cases with SNHL had DM > 2years while only 23.9% of 
cases with SNHL had DM <2 years. About 41.3% cases with SNHL had DM 
>4 years. 
CONTROL OF DISEASE: 
 Occurrences of retinopathy and SNHL in diabetics depends upon the 
control of the disease. Most studies have stated that diabetic related 
complications such as retinopathy and SNHL can be prevented or delay their 
onset by controlling DM22,2,4. 
Reduction in blood glucose or HbA1C concentrations through tight 
blood glucose control in diabetes reduces the rate of progression of 
retinopathy. 
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In our study cases with HbA1C >7 , 71.7% of them had retinopathy 
than compared to only 2.1% cases who had HbA1C <7. 
43.47% of cases having retinopathy had HbA1C >8. 
Similarly 84.7% of cases having SNHL had HbA1C >7. About 41.35% cases 
with SNHL had HbA1C >8. 
 CORRELATION BETWEEN SNHL AND RETINOPATHY AMONG 
CASES: 
In our study 47.8% of cases had SNHL >41dB (>/=moderate SNHL) 
and these same cases had retinopathy of grade 2 NPDR or higher severity of 
retinopathy. 
Its statistically highly significant that diabetics (cases) with greater 
SNHL have more severe retinopathy with P value: - <0.001.  
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SUMMARY 
 our study was aimed to determine the correlation between SNHL and 
Diabetic Retinopathy among diabetics. 
92 participants were included in the study, who were divided into cases 
and controls with 46 in each group. In whom relevant history regarding their 
diabetes was noted i.e age at diagnosis of diabetes, duration of the diabetes, 
nature and duration of treatment received, glycemic control and compliance to 
the treatment. Patients were evaluated for their HbA1C levels, hypertension, 
lipid profile and renal parameters. 
Each participant’s diabetic retinopathy, SNHL and visual acuity status 
was classified accordingly. 
In our study 73.9% of cases had diabetic retinopathy and 89% of cases 
had sensory neural hearing loss with significant P value. 
60.8% cases with >2years of DM had retinopathy. About 39.1% cases 
of retinopathy had DM for >4 years. 4 out of 5 cases of PDR had DM > 6 
years. 
65.2% of cases with SNHL had DM > 2years of which 41.3% cases 
with SNHL had DM >4 years. 
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 Cases with HbA1C >7 , 71.7% of them had retinopathy of which 
43.47% of them had HbA1C >8. Similarly 84.7% of cases having SNHL had 
HbA1C >7 of which 41.35% had HbA1C >8. 
47.8% of cases having SNHL >41dB (>/=moderate SNHL) had 
retinopathy of grade 2 NPDR or higher severity of retinopathy. Its highly 
significant that diabetics with greater SNHL have more severe retinopathy 
with P value: - <0.001. 
Our study found a significant correlation between SNHL and  diabetic 
retinopathy. The other factor which had a significant correlation was duration 
of diabetes with the severity of retinopathy and SNHL, glycemic control and 
the disease progression. 
Other factors which did not have any significant correlation were  Age 
of the patient, gender of the patient. 
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CONCLUSION 
A statistically significant correlation was found between SNHL and the 
severity of diabetic retinopathy. More severe grades of SNHL and  retinopathy 
manifesting in patients with higher levels of HbA1C and prolonged duration of 
DM. 
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PROFORMA FOR REGISTRATION OF SUBJECTS FOR 
DISSERTATION 
NAME:     AGE/SEX:   O.P/I.P 
No. 
ADDRESS: 
 
CHIEF COMPLAINTS: 
DURATION OF ILLNESS: 
HISTORY OF PRESENT ILLNESS: 
PAST HISTORY: 
TREATMENT HISTORY: 
FAMILY HISTORY: 
PERSONAL HISTORY: 
GENERAL PHYSICAL EXAMINATION:- 
PULSE:    BP: 
SYSTEMIC EXAMINATION: 
CVS 
RS 
  
 
CNS 
GIT 
ENT EXAMINATION: 
EAR:     LEFT     RIGHT 
PRE & POST AURICULAR: 
PINNA: 
EAC: 
TYMPANIC MEMBRANE: 
TUNNING FORK TESTS 
RINNE’S: 
WEBER’S 
ABC 
NOSE: 
ORAL CAVITY & OROPHARYNX: 
OPHTHALMOLOGICAL EXAMINATION:  
LEFT     RIGHT 
EYE LID: 
CONJUCTIVA: 
  
 
CORNEA: 
PUPIL: 
LENS: 
SLIT LAMP: 
OPHTHALMOSCOPY: 
 
INVESTIGATIONS: 
CBC 
FBS 
PPBS 
HbA1C 
FASTING LIPID PROFILE 
URINE ANALYSIS 
PTA 
VISION TEST 
FUNDOSCOPY 
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iii
MODERATELY 
SEVERE-3 GRADE-2 GRADE-2 BOTH-3
iv SEVERE-4 GRADE-3
v PROFOUND-5 GRADE-4
1 damiyanthi 110051 52 0 7 12.7 204 320 3 0 3 6/18 2
2 sulochana 110257 48 0 5 7.4 158 284 2 0 2 6/9 2
3 shageela 110872 52 0 4 8.6 182 289 2 0 2 6/9 3
4 merryamal 110031 54 0 8 11.8 163 384 3 0 6 2 6/24 2
5 ezhil 110036 46 0 3 7.2 148 186 1 0 1 6/9 2
6 kazhimohi 110111 51 0 5 8.1 150 306 2 0 2 6/18 2
7 sabina begum 110171 40 0 2 7.7 146 259 2 0 1 6/9 2
8 kalavathi 110002 44 0 4 8.7 151 277 2 0 2 6/18 3
9 jayamaal 110099 42 0 1 7.1 140 176 1 0 0 6/6 2
10 poovamal 110078 50 0 5 9.2 198 229 2 0 5 1 6/36 3
11 abdulla 110055 42 1 0.5 8.3 155 194 1 0 1 6/9 2
12 rafeeq 101245 43 1 3 7.1 126 206 2 1 1 6/9 2
13 raman 110332 37 1 1 7.9 147 207 0 0 0 6/6 2
14 manohar 102036 39 1 2.5 7.7 123 191 1 0 1 6/9 2
15 krishna 105484 40 1 3 7 117 174 0 0 0 6/6 2
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16 devi 111025 52 0 9 12.94 281 412 4 0 4 6/24 2
17 manivannan 123546 54 1 6.5 9.9 190 340 3 0 5 1 6/24 3
18 suresh 102590 32 1 2 7.6 150 206 1 0 0 6/9 2
19 pista 111011 30 0 0.75 6.8 109 182 0 0 0 6/6 0
20 mohan 20148 46 1 3.5 7.1 138 240 1 0 1 6/9 2
21 david 301254 53 1 8 10.5 150 358 3 0 4 6/24 3
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29 aiysha 213587 43 0 2 7 170 249 1 0 1 6/9 2
30 suresh 236457 51 1 6 9 158 276 2 0 2 6/18 2
31 ramani 410256 50 0 5 7.8 145 214 2 0 2 6/18 2
32 munusamy 887925 45 1 2 6.7 119 220 1 0 1 6/9 2
33 babu khan 455628 53 1 7 11 209 418 3 0 3 6/18 2
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40 balu 223569 49 1 6 8.7 151 228 2 0 3 6/18 2
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43 jayashree 113240 41 0 1 7.2 109 189 1 0 0 6/9 2
44 gayathri 789580 39 0 2 9 169 247 2 0 2 6/18 2
45 selvam 12569 54 1 9 9.9 153 289 3 0 6 2 6/36 2
46 prabhu 101578 50 1 3.75 8 143 199 2 0 2 6/9 2
1 salman 24 1 0 5.4 89 132 0 0 6/6
2 divya 28 0 0 4.46 92 140 0 0 6/6
3 vasanthi 48 0 0 5.7 95 129 0 0 6/9
4 kavitha 35 0 0 6 83 139 0 0 6/9
5 ravikumari 54 0 0 5.2 77 138 2 1 6/18
6 sultana 48 0 0 5.6 98 135 2 0 6/9
7 kumar 50 1 0 5.5 80 128 1 0 6/9
8 raghav 30 1 0 4.6 79 121 0 0 6/6
9 rajshekher 52 1 0 5.12 88 128 1 2 6/18
10 rosy 46 0 0 5.64 72 134 0 1 6/9
11 shashikala 53 0 0 5.5 95 129 3 0 6/9
12 ravi 32 1 0 5 82 122 0 0 6/6
13 sathish 25 1 0 4.8 72 119 0 0 6/6
14 krishnan 36 1 0 5.9 86 130 0 0 6/6
15 kadhar khan 50 1 0 4.9 92 139 3 0 6/9
16 mohanapriya 29 0 0 5.1 85 137 0 0 6/6
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20 subhadra 40 0 0 5.17 97 122 1 0 6/9
21 ganesh 52 1 0 5.6 89 137 1 0 6/9
22 mahesh 39 1 0 5.2 70 122 0 0 6/9
23 sukesh 20 1 0 4.6 87 128 0 0 6/6
24 abdulla 41 1 0 5.4 99 131 0 0 6/9
25 naveen 30 1 0 4.7 71 120 0 0 6/6
26 shabri 49 1 0 5 88 125 0 0 6/9
27 vellamal 41 0 0 5.69 98 131 0 0 6/9
28 pachiyammal 50 0 0 5.54 100 136 0 2 6/18
29 sabina 35 0 0 4.8 74 132 0 0 6/6
30 shareef 42 1 0 5.7 94 121 0 0 6/6
31 kasiyammal 45 0 0 5.31 99 125 0 0 6/9
32 praveen 30 1 0 5 92 126 0 0 6/6
33 suguna 31 0 0 5.7 100 139 0 0 6/6
34 gopi 53 1 0 5.64 98 137 1 1 6/9
35 soloman 52 1 0 4.68 92 139 2 0 6/9
36 shabeer 49 1 0 5 90 121 0 0 6/9
37 dhandapani 50 1 0 4.98 99 139 2 2 6/18
38 saravanan 33 1 0 5.41 94 128 0 0 6/6
39 rameez 32 1 0 5 87 135 1 0 6/6
40 ashwini 24 0 0 4.8 69 122 0 0 6/6
41 bindhu 34 0 0 5.5 77 133 0 0 6/6
42 arun 39 1 0 5.29 99 134 0 0 6/6
43 vivek 28 1 0 4.9 75 136 0 0 6/6
44 murugeshan 54 1 0 5.16 80 110 1 0 6/9
45 ajay 26 1 0 5 71 130 0 0 6/6
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Photograph-1. ENT examination instruments. 
 
 
Photograph -2. ENT examination cubicle. 
  
 
 
Photograph -3. PTA sheet 
  
 
 
Photograph -4. Ophthalmoscope. 
 
Photograph -5. Snellen chart. 
  
 
 
Photograph-6. Fundoscope. 
 
 
Photograph -7. Fundoscopic examination. 
 
  
 
 
PHOTOGRAPH -8. PTA IN PROGRESS 
 
 
PHOTOGRAPH -9. PTA MACHINE. 
 
  
 
 
